RESUMEN
OBJECTIVE: to determine the association between the expression of lipoprotein lipase (LPL) and c-MYC genes inperipheral blood cells of chronic lymphocytic leukemia (CLL) patients affected by the Chornobyl catastrophedepending on the mutational status of IGHV genes. METHODS: Analysis was performed in the group of 69 CLL patients irradiated due to the Chornobyl NPP accident (58clean-up workers of 1986 year, 6 inhabitants of radionuclide contaminated areas, and 5 evacuees). The IGHV genemutational status was studied by polymerase chain reaction (PCR) followed by direct sequencing. LPL and c-MYCexpression was evaluated by Quantitative Real-time PCR. Data were analyzed with the SPSS software package, version 20.0. RESULTS: Relative LPL expression levels in CLL samples ranged from 0 to 1663.5 (mean 138.47 ± 30.69, median 26.1).A strong correlation between individual LPL expression levels and IGHV mutational status was found (r = 0.684;p < 0.0001). The average relative c-MYC expression level was 5.7 ± 0.87 (median 2.86; range 0-48.5). No association between c-MYC expression and IGHV mutational status was found. Among unmutated IGHV cases, a correlationbetween LPL and c-MYC gene expression levels was identified: r = 0.351; p = 0.013. CONCLUSIONS: Our data confirm the dominant concept that unmutated IGHV CLL cases are more sensitive to the actionof proliferative stimuli compared to mutated IGHV CLL cases. This is manifested by an increase in the expression ofa functionally significant LPL gene, is one for the strongest negative prognostic markers in CLL.
Asunto(s)
Accidente Nuclear de Chernóbil , Genes de las Cadenas Pesadas de las Inmunoglobulinas , Leucemia Linfocítica Crónica de Células B/genética , Lipoproteína Lipasa/genética , Proteínas Proto-Oncogénicas c-myc/genética , Exposición a la Radiación/efectos adversos , Traumatismos por Radiación/genética , Anciano , Contaminantes Radiactivos del Aire/efectos adversos , Socorristas , Femenino , Contaminación Radiactiva de Alimentos , Regulación de la Expresión Génica , Humanos , Leucemia Linfocítica Crónica de Células B/etiología , Leucemia Linfocítica Crónica de Células B/inmunología , Leucemia Linfocítica Crónica de Células B/patología , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/patología , Leucocitos Mononucleares/efectos de la radiación , Lipoproteína Lipasa/inmunología , Masculino , Persona de Mediana Edad , Mutación , Pronóstico , Proteínas Proto-Oncogénicas c-myc/inmunología , Traumatismos por Radiación/etiología , Traumatismos por Radiación/inmunología , Traumatismos por Radiación/patología , Radioisótopos , Contaminantes Radiactivos del Suelo/efectos adversos , UcraniaRESUMEN
For three decades, the LPL-specific monoclonal antibody 5D2 has been used to investigate LPL structure/function and intravascular lipolysis. 5D2 has been used to measure LPL levels, block the triglyceride hydrolase activity of LPL, and prevent the propensity of concentrated LPL preparations to form homodimers. Two early studies on the location of the 5D2 epitope reached conflicting conclusions, but the more convincing report suggested that 5D2 binds to a tryptophan (Trp)-rich loop in the carboxyl terminus of LPL. The same loop had been implicated in lipoprotein binding. Using surface plasmon resonance, we showed that 5D2 binds with high affinity to a synthetic LPL peptide containing the Trp-rich loop of human (but not mouse) LPL. We also showed, by both fluorescence and UV resonance Raman spectroscopy, that the Trp-rich loop binds lipids. Finally, we used X-ray crystallography to solve the structure of the Trp-rich peptide bound to a 5D2 Fab fragment. The Trp-rich peptide contains a short α-helix, with two Trps projecting into the antigen recognition site. A proline substitution in the α-helix, found in mouse LPL, is expected to interfere with several hydrogen bonds, explaining why 5D2 cannot bind to mouse LPL.
Asunto(s)
Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/inmunología , Lipoproteína Lipasa/química , Lipoproteína Lipasa/inmunología , Animales , Sitios de Unión , Humanos , Ratones , TriptófanoRESUMEN
PURPOSE OF REVIEW: Sepsis is a common syndrome of multiorgan system dysfunction caused by a dysregulated inflammatory response to an infection and is associated with high rates of mortality. Plasma lipid and lipoprotein levels and composition change profoundly during sepsis and have emerged as both biomarkers and potential therapeutic targets for this condition. The purpose of this article is to review recent progress in the understanding of the molecular regulation of lipid metabolism during sepsis. RECENT FINDINGS: Patients who experience greater declines in high-density lipoprotein during sepsis are at much greater risk of succumbing to organ failure and death. Although the causality of these findings remains unclear, all lipoprotein classes can sequester and prevent the excessive inflammation caused by pathogen-associated lipids during severe infections such as sepsis. This primordial innate immune function has been best characterized for high-density lipoproteins. Most importantly, results from human genetics and preclinical animal studies have suggested that several lipid treatment strategies, initially designed for atherosclerosis, may hold promise as therapies for sepsis. SUMMARY: Lipid and lipoprotein metabolism undergoes significant changes during sepsis. An improved understanding of the molecular regulation of these changes may lead to new opportunities for the treatment of sepsis.
Asunto(s)
Proteínas de Transferencia de Ésteres de Colesterol/genética , Metabolismo de los Lípidos/genética , Lipoproteínas HDL/sangre , Insuficiencia Multiorgánica/genética , Proproteína Convertasa 9/genética , Sepsis/genética , Animales , Anticolesterolemiantes/uso terapéutico , Apolipoproteínas C/uso terapéutico , Biomarcadores/sangre , Proteínas de Transferencia de Ésteres de Colesterol/antagonistas & inhibidores , Proteínas de Transferencia de Ésteres de Colesterol/sangre , Proteínas de Transferencia de Ésteres de Colesterol/inmunología , Regulación de la Expresión Génica , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Inmunidad Innata , Metabolismo de los Lípidos/efectos de los fármacos , Metabolismo de los Lípidos/inmunología , Lipoproteína Lipasa/sangre , Lipoproteína Lipasa/genética , Lipoproteína Lipasa/inmunología , Lipoproteínas HDL/genética , Lipoproteínas HDL/inmunología , Insuficiencia Multiorgánica/sangre , Insuficiencia Multiorgánica/mortalidad , Insuficiencia Multiorgánica/prevención & control , Inhibidores de PCSK9 , Fragmentos de Péptidos/uso terapéutico , Proproteína Convertasa 9/sangre , Proproteína Convertasa 9/inmunología , Sepsis/sangre , Sepsis/tratamiento farmacológico , Sepsis/mortalidad , Análisis de SupervivenciaRESUMEN
We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Hipertrigliceridemia/tratamiento farmacológico , Rituximab/uso terapéutico , Triglicéridos/sangre , Anticuerpos/sangre , Enfermedades Autoinmunes/diagnóstico , Linfocitos B/citología , Heterocigoto , Humanos , Hipertrigliceridemia/diagnóstico , Lipoproteína Lipasa/inmunología , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Receptores de LDL/genéticaAsunto(s)
Anemia/diagnóstico , Epítopos/inmunología , Infecciones por Herpesviridae/inmunología , Herpesviridae/inmunología , Hiperlipoproteinemias/diagnóstico , Púrpura Trombocitopénica Idiopática/diagnóstico , Trombocitopenia/diagnóstico , Adulto , Anemia/terapia , Autoanticuerpos/sangre , Antígenos CD59/inmunología , Humanos , Hiperlipoproteinemias/terapia , Inmunosupresores/uso terapéutico , Lipoproteína Lipasa/inmunología , Masculino , Metilprednisolona/uso terapéutico , Imitación Molecular , Plasmaféresis , Púrpura Trombocitopénica Idiopática/terapia , Receptores de Lipoproteína/inmunología , Rituximab/uso terapéutico , Trombocitopenia/terapia , Proteínas Virales/inmunologíaRESUMEN
Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism. Due to its catalytic activity, LPL is involved in metabolic pathways exploited by various solid and hematologic malignancies to provide an extra energy source to the tumor cell. We and others described a link between the expression of LPL in the tumor cell and a poor clinical outcome of patients suffering Chronic Lymphocytic Leukemia (CLL). This leukemia is characterized by a slow accumulation of mainly quiescent clonal CD5 positive B cells that infiltrates secondary lymphoid organs, bone marrow and peripheral blood. Despite LPL being found to be a reliable molecular marker for CLL prognosis, its functional role and the molecular mechanisms regulating its expression are still matter of debate. Herein we address some of these questions reviewing the current state of the art of LPL research in CLL and providing some insights into where currently unexplored questions may lead to.
Asunto(s)
Linfocitos B/inmunología , Biomarcadores de Tumor/genética , Antígenos CD5/genética , Leucemia Linfocítica Crónica de Células B/diagnóstico , Lipoproteína Lipasa/genética , Linfocitos B/patología , Biomarcadores de Tumor/inmunología , Médula Ósea/inmunología , Médula Ósea/patología , Antígenos CD5/inmunología , Expresión Génica , Humanos , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/inmunología , Leucemia Linfocítica Crónica de Células B/mortalidad , Lipoproteína Lipasa/inmunología , Pronóstico , Análisis de SupervivenciaRESUMEN
We report a case of severe type I hyperlipoproteinemia caused by autoimmunity against lipoprotein lipase (LPL) in the context of presymptomatic Sjögren's syndrome. A 7-year-old mixed race (Caucasian/African American) girl was admitted to the intensive care unit at Vanderbilt Children's Hospital with acute pancreatitis and shock. She was previously healthy aside from asthma and history of Hashimoto's thyroiditis. Admission triglycerides (TGs) were 2191 mg/dL but returned to normal during the hospital stay and in the absence of food intake. At discharge, she was placed on a low-fat, low-sugar diet. She did not respond to fibrates, prescription fish oil, metformin, or orlistat, and during the following 2 years, she was hospitalized several times with recurrent pancreatitis. Except for a heterozygous mutation in the promoter region of LPL, predicted to have no clinical significance, she had no further mutations in genes known to affect TG metabolism and to cause inherited type I hyperlipoproteinemia, such as APOA5, APOC2, GPIHBP1, or LMF1. When her TG levels normalized after incidental use of prednisone, an autoimmune mechanism was suspected. Immunoblot analyses showed the presence of autoantibodies to LPL in the patient's plasma. Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy. While on hydroxychloroquine, she underwent a supervised high-fat meal challenge and showed normal ability to metabolize TG. For the past 3 years and 6 months, she has had TG consistently <250 mg/dL, and no symptoms of, or readmissions for, pancreatitis.
Asunto(s)
Autoinmunidad/genética , Hiperlipoproteinemia Tipo I/genética , Lipoproteína Lipasa/genética , Triglicéridos/sangre , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoinmunidad/inmunología , Niño , Femenino , Heterocigoto , Humanos , Hiperlipoproteinemia Tipo I/sangre , Hiperlipoproteinemia Tipo I/inmunología , Hiperlipoproteinemia Tipo I/fisiopatología , Lipoproteína Lipasa/inmunología , Mutación , Prednisona/administración & dosificación , Síndrome de Sjögren/genética , Síndrome de Sjögren/fisiopatologíaRESUMEN
GPIHBP1, an endothelial cell protein, binds LPL in the interstitial spaces and shuttles it to its site of action inside blood vessels. For years, studies of human GPIHBP1 have been hampered by an absence of useful antibodies. We reasoned that monoclonal antibodies (mAbs) against human GPIHBP1 would be useful for 1) defining the functional relevance of GPIHBP1's Ly6 and acidic domains to the binding of LPL; 2) ascertaining whether human GPIHBP1 is expressed exclusively in capillary endothelial cells; and 3) testing whether GPIHBP1 is detectable in human plasma. Here, we report the development of a panel of human GPIHBP1-specific mAbs. Two mAbs against GPIHBP1's Ly6 domain, RE3 and RG3, abolished LPL binding, whereas an antibody against the acidic domain, RF4, did not. Also, mAbs RE3 and RG3 bound with reduced affinity to a mutant GPIHBP1 containing an Ly6 domain mutation (W109S) that abolishes LPL binding. Immunohistochemistry studies with the GPIHBP1 mAbs revealed that human GPIHBP1 is expressed only in capillary endothelial cells. Finally, we created an ELISA that detects GPIHBP1 in human plasma. That ELISA should make it possible for clinical lipidologists to determine whether plasma GPIHBP1 levels are a useful biomarker of metabolic or vascular disease.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Lipoproteína Lipasa/inmunología , Receptores de Lipoproteína/inmunología , Triglicéridos/metabolismo , Animales , Sitios de Unión/inmunología , Línea Celular , Drosophila , Células Endoteliales/enzimología , Células Endoteliales/inmunología , Humanos , Lipoproteína Lipasa/antagonistas & inhibidores , Lipoproteína Lipasa/aislamiento & purificación , Ratones , Receptores de Lipoproteína/genética , Triglicéridos/inmunologíaRESUMEN
Angiopoietin-like 4 (Angptl4), a secreted protein, is an important regulator to irreversibly inhibit lipoprotein lipase (LPL) activity. Macrophage LPL contributes to foam cell formation via a so-called"molecular bridge" between lipoproteins and receptors on cell surface. It has been reported that macrophage ANGPTL4 suppresses LPL activity, foam cell formation and inflammatory gene expression to reduce atherosclerosis development. Recently, some studies demonstrated that microRNA-134 is upregulated in atherosclerotic macrophages. Here we demonstrate that miR-134 directly binds to 3'UTR of ANGPTL4 mRNA to suppression the expression of ANGPTL4. To investigate the potential roles of macrophage miR-134, THP-1 macrophages were transfected with miR-134 mimics or inhibitors. Our results showed that LPL activity and protein were dramatically increased. We also found that miR-134 activated LPL-mediated lipid accumulation. Collectively, our findings indicate that miR-134 may regulate lipid accumulation and proinfiammatory cytokine secretion in macrophages by targeting the ANGPTL4 gene. Our results have also suggested a promising and potential therapeutic target for atherosclerosis.
Asunto(s)
Angiopoyetinas/inmunología , Inflamación/inmunología , Metabolismo de los Lípidos/inmunología , Lipoproteína Lipasa/inmunología , Macrófagos/inmunología , MicroARNs/inmunología , Proteína 4 Similar a la Angiopoyetina , Línea Celular , Activación Enzimática , Humanos , Macrófagos/enzimología , Transducción de Señal/inmunologíaRESUMEN
Lipasin/Angptl8 is a feeding-induced hepatokine that regulates triglyceride (TAG) metabolism; its therapeutical potential, mechanism of action, and relation to the lipoprotein lipase (LPL), however, remain elusive. We generated five monoclonal lipasin antibodies, among which one lowered the serum TAG level when injected into mice, and the epitope was determined to be EIQVEE. Lipasin-deficient mice exhibited elevated postprandial activity of LPL in the heart and skeletal muscle, but not in white adipose tissue (WAT), suggesting that lipasin suppresses the activity of LPL specifically in cardiac and skeletal muscles. Consistently, mice injected with the effective antibody or with lipasin deficiency had increased postprandial cardiac LPL activity and lower TAG levels only in the fed state. These results suggest that lipasin acts, at least in part, in an endocrine manner. We propose the following model: feeding induces lipasin, activating the lipasin-Angptl3 pathway, which inhibits LPL in cardiac and skeletal muscles to direct circulating TAG to WAT for storage; conversely, fasting induces Angptl4, which inhibits LPL in WAT to direct circulating TAG to cardiac and skeletal muscles for oxidation. This model suggests a general mechanism by which TAG trafficking is coordinated by lipasin, Angptl3 and Angptl4 at different nutritional statuses.
Asunto(s)
Angiopoyetinas/metabolismo , Anticuerpos Monoclonales/administración & dosificación , Lipoproteína Lipasa/biosíntesis , Hormonas Peptídicas/inmunología , Tejido Adiposo/metabolismo , Proteína 3 Similar a la Angiopoyetina , Proteína 4 Similar a la Angiopoyetina , Proteína 8 Similar a la Angiopoyetina , Proteínas Similares a la Angiopoyetina , Animales , Anticuerpos Monoclonales/inmunología , Humanos , Lipoproteína Lipasa/inmunología , Lipoproteína Lipasa/metabolismo , Ratones , Músculo Esquelético/metabolismo , Miocardio/metabolismo , Hormonas Peptídicas/deficiencia , Hormonas Peptídicas/uso terapéutico , Periodo Posprandial , Triglicéridos/sangreRESUMEN
Introdução: as doenças cardiovasculares acometem milhares de pessoas no mundo. Destas, a doença arterosclerótica está entre as de maior morbimortalidade. Para a avaliação da necessidade de intervenções hemodinâmicas e/ou revascularização miocárdica, há a necessidade da realização do cateterismo (CATE), procedimento de imagem indicado para evidenciar pontos de obstrução e determinar a melhor estratégia cirúrgica. Para a realização do CATE utiliza-se heparina sódica (5000 UI) in bolus. Atualmente, sabe-se que a heparina interfere no remodelamento de partículas lipoproteicas por liberação da lipoproteína lipase (LPL) e da lipase hepática (LH), essa ação pode alterar o transporte reverso do colesterol (TRC), em função de modificações no metabolismo das lipoproteínas. Métodos: foram selecionados por conveniência 20 pacientes, 10 do sexo masculino e 10 do sexo feminino, ambos os sexos, entre 45 e 73 anos, admitidos no Hospital Ana Neri, submetidos à cineangiocoronariografia (CATE)...
Introduction: cardiovascular diseases affect thousands of people worldwide. Of these, the atherosclerotic disease is one of the most morbidity and mortality. To evaluate the need for hemodynamic interventions and / or CABG, the catheterization (CATE) is performed, an imaging procedure to evidence obstruction and to determine the best surgical strategy. To perform CATE, is necessary to use in bolus sodium heparin (5000 IU). Currently, it is known that heparin interferes with the remodeling of the lipoprotein particles by releasing lipoprotein lipase (LPL) and hepatic lipase (HL), this action may alter the reverse cholesterol transport (TRC), by changes in lipoprotein metabolism. Methods: were selected by convenience 20 patients, 10 male and 10 female, both gender, between 45 and 73 years old, admitted to the Hospital Ana Neri, who underwent coronary angiography (CATE)...
Asunto(s)
Humanos , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/patología , Lipoproteína Lipasa/administración & dosificación , Lipoproteína Lipasa/efectos adversos , Lipoproteína Lipasa/inmunología , Lipoproteína Lipasa/sangre , Lipoproteínas HDL/administración & dosificación , Lipoproteínas HDL/análisis , Lipoproteínas HDL/sangreRESUMEN
Atherosclerosis is a lipid disorder disease characterized by chronic blood vessel wall inflammation driven by the subendothelial accumulation of macrophages. Studies have shown that lipoprotein lipase (LPL) participates in lipid metabolism, but it is not yet known whether post-transcriptional regulation of LPL gene expression by microRNAs (miRNAs) occurs in vivo. Here, we tested that miR-467b provides protection against atherosclerosis by regulating the target gene LPL which leads to reductions in LPL expression, lipid accumulation, progression of atherosclerosis and production of inflammatory cytokines in apolipoprotein E knockout (apoE(-/-)) mice. Treatment of apoE(-/-) mice with intra-peritoneal injection of miR-467b agomir led to decreased blood plasma levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1ß and monocyte chemotactic protein-1 (MCP-1). Using Western blots and real time PCR, we determined that LPL expression in aorta and abdominal cavity macrophages were significantly down-regulated in the miR-467b agomir group. Furthermore, systemic treatment with miR-467b antagomir accelerated the progression of atherosclerosis in the aorta of apoE(-/-) mice. The present study showed that miR-467b protects apoE(-/-) mice from atherosclerosis by reducing lipid accumulation and inflammatory cytokine secretion via downregulation of LPL expression. Therefore, targeting miR-467b may offer a promising strategy to treat atherosclerotic vascular disease.
Asunto(s)
Apolipoproteínas E/genética , Aterosclerosis/inmunología , Citocinas/inmunología , Inflamación/inmunología , Metabolismo de los Lípidos/inmunología , Lipoproteína Lipasa/inmunología , MicroARNs/farmacología , Animales , Aterosclerosis/prevención & control , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Inflamación/prevención & control , Metabolismo de los Lípidos/efectos de los fármacos , Lipoproteína Lipasa/biosíntesis , Masculino , Ratones , Ratones Noqueados , Resultado del TratamientoRESUMEN
CONTEXT: Type 1 hyperlipoproteinemia (T1HLP) in childhood is most often due to genetic deficiency of lipoprotein lipase (LPL) or other related proteins. OBJECTIVE: The aim was to report a case of marked hypertriglyceridemia and recurrent acute pancreatitis due to the presence of LPL autoantibody in a young girl who was subsequently diagnosed with Sjögren's syndrome. SUBJECT AND METHODS: A 9-yr-old African-American girl presented with acute pancreatitis and serum triglycerides of 4784 mg/dl. Strict restriction of dietary fat reduced serum triglycerides, but she continued to experience recurrent pancreatitis. Approximately 18 months thereafter, she developed transient pauciarticular arthritis with elevated serum antinuclear antibody (>1:1280). Minor salivary gland biopsy revealed chronic sialadenitis with a dense periductal lymphocytic aggregate suggestive of Sjögren's syndrome. Genomic DNA was analyzed for LPL, GPIHBP1, APOA5, APOC2, and LMF1. Immunoblotting was performed to detect serum LPL autoantibody. RESULTS: The patient had no disease-causing variants in LPL, GPIHBP1, APOA5, APOC2, or LMF1. Immunoblotting revealed serum LPL antibody. The patient responded to immunosuppressive therapy for Sjögren's syndrome with resolution of hypertriglyceridemia. CONCLUSIONS: Unexplained T1HLP in childhood could be secondary to LPL deficiency induced by autoantibodies. Therefore, diagnosis of autoimmune T1HLP should be entertained if clinical features are suggestive of an autoimmune process.
Asunto(s)
Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Hiperlipoproteinemia Tipo I/inmunología , Lipoproteína Lipasa/inmunología , Pancreatitis Aguda Necrotizante/inmunología , Síndrome de Sjögren/inmunología , Enfermedades Autoinmunes/diagnóstico , Niño , Femenino , Humanos , Hiperlipoproteinemia Tipo I/complicaciones , Hiperlipoproteinemia Tipo I/diagnóstico , Pancreatitis Aguda Necrotizante/complicaciones , Pancreatitis Aguda Necrotizante/diagnóstico , Síndrome de Sjögren/complicacionesRESUMEN
BACKGROUND: Anti-lipoprotein lipase antibodies have been described in rare cases of patients with hypertriglyceridemia. However, no systematic study evaluating these antibodies in patients with this lipid abnormality has been undertaken. OBJECTIVES: To analyze the correlation of anti-lipoprotein lipase (anti-LPL) antibodies with other laboratory findings in patients with hypertriglyceridemia but no autoimmune disease. METHODS: We evaluated 44 hypertriglyceridemic patients without autoimmune disease. Clinical and laboratory evaluations included analyses of comorbidities, fasting lipid profile and anti-LPL antibodies. RESULTS: Mean patient age was 55 +/- 10 years; 46% of the patients were female and 64% were Caucasian. The mean disease duration was 94.4 months and mean body mass index 28.7 +/- 3.6 kg/m2; 34.0% were diabetic, 25.0% were obese, 72.7% had systemic arterial hypertension, 75% were sedentary, 15.9% were smokers, 56.8% had a family history of dyslipidemia, 45.5% had a family history of coronary insufficiency, 20.5% had acute myocardial infarction, 9.0% had undergone revascularization and 11.0% angioplasty, 79.5% were being treated with statins and 43.2% were taking fibrates. Median triglyceride levels were 254 mg/dl (range 100-3781 mg/dl), and total cholesterol level was 233 t 111 mg/dl. High-density lipoprotein was 42.6 +/- 15.4 mg/dl, low-density lipoprotein 110.7 +/- 42.4 mg/dl and very low-density lipoprotein 48 +/- 15 mg/dl. Anti-LPL antibodies were identified in 2 patients (4.5%), both of whom had a family history of dyslipidemia, coronary insufficiency and acute myocardial infarction; one had undergone myocardial revascularization and percutaneous transluminal coronary angioplasty, and both were using fibrates and had normal triglyceride levels. CONCLUSIONS: Our findings demonstrate a correlation between the immune response and dyslipoproteinemia in hypertriglyceridemic patients, suggesting that autoimmune disease contributes to the dyslipidemia process.
Asunto(s)
Autoanticuerpos/sangre , Enfermedades Autoinmunes , Autoinmunidad , Hipertrigliceridemia/inmunología , Lipoproteína Lipasa/inmunología , Triglicéridos/sangre , Aterosclerosis/sangre , Aterosclerosis/etiología , Aterosclerosis/inmunología , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Humanos , Hipertrigliceridemia/complicaciones , Hipertrigliceridemia/enzimología , Lipoproteína Lipasa/sangre , Masculino , Persona de Mediana Edad , Pronóstico , Estudios RetrospectivosRESUMEN
INTRODUCTION: Premature development of atherosclerosis in systemic lupus erythematosus has been widely reported. Anti-lipoprotein lipase antibody may be one cause contributing to this disorder. OBJECTIVE: To assess the extent of coronary risk due to autoimmune antibodies in terms of carotid plaque in lupus patients. PATIENTS AND METHODS: We compared 114 documented lupus patients with 111 normal controls matched for sex and age. Anti-lipoprotein lipase (A-LPL), anti-oxidized low density lipoprotein (A-OXLDL), and anti-low density lipoprotein (A-LDL) were measured by enzme-linked immunoabsorbent assay. Low density lipoprotein-triglyceride (LDL-Trig) and high density lipoprotein-triglyceride (HDL-Trig) were also measured. Plaque was measured by bilateral carotid ultrasound. RESULTS: 45.6% of patients tested positive for A-LPL, and 34.4% for A-OXLDL. 44% of normal controls tested positive for A-LPL, and 20% for A-OXLDL. Risk increased sharply in subgroups with increased antibody levels. Patients with A-LPL and A-OXLDL > 0.40 (n = 12) showed coronary risk correlations of: A-LPL x LDL-Trig = 0.7008, P = 0.0111; bilateral ultrasound vs total cholesterol = 0.62205, P = 0.0308; LDL-Trig vs myocardial infarction (MI) = 0.76562, P = 0.0037; total triglycerides vs MI = 0.78191, P = 0.0027); LDL-Trig/LDL-cholesterol vs MI = 0.80493, P = 0.0016; A-OXLDL vs USBL = 0.71930, P = 0.0084. Correlations of SLEDAI with risk variables were highly significant only in subgroups of elevated antibody levels (SLEDAI x A-OXLDL = 0.70366, P = 0.0107). CONCLUSION: A-LPL initiates the development of LDL mutations, followed by antibody production, plaque formation and coronary risk in some SLE patients.
Asunto(s)
Aterosclerosis/inmunología , Autoanticuerpos/inmunología , Metabolismo de los Lípidos/inmunología , Lipoproteína Lipasa/inmunología , Lipoproteínas LDL/inmunología , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aterosclerosis/etiología , Femenino , Humanos , Lupus Eritematoso Sistémico/complicaciones , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
INTRODUÇÃO: O desenvolvimento prematuro de aterosclerose em lúpus eritematoso sistêmico tem sido amplamente divulgado. Anticorpo antilipoproteína lipase pode ser uma das causas que contribuem para esta doença. OBJETIVO: Avaliar o grau de risco coronariano devido a autoanticorpos em termos de placa carotídea em pacientes com lúpus. PACIENTES E MÉTODOS: Comparamos 114 pacientes com lúpus documentado e 111 controles normais pareados por sexo e idade. Antilipoproteína lipase (A-LPL), antilipoproteínas de baixa densidade oxidada (A-OXLDL), e antilipoproteínas de baixa densidade (A-LDL) foram medidos pelo teste imunoenzimático - ELISA. LDL-triglicéride (LDL-Trig) e HDL-Trig também foram dosados. A placa foi medida por ultrassom bilateral de carótida. RESULTADOS: 45,6 por cento dos pacientes foram positivos para A-LDL e 34,4 por cento para A-OXLDL; 44 por cento dos controles foram positivos para A-LDL e 20 por cento para A-OXLDL. O risco aumentou acentuadamente nos subgrupos com níveis elevados de anticorpos. Pacientes com A-LDL e A-OXLDL > 0,40 (n = 12) mostraram correlações de risco coronariano de: ALDL vs LDL-Trig = 0,7008, P = 0,0111; ultrassom bilateral vs colesterol = 0,62205, P = 0,0308; LDL-Trig vs infarto do miocárdio (IM) = 0,76562, P =0,0037; triglicerídeos totais vs IM = 0,78191, P = 0.0027); LDL-Trig/LDL-colesterol vs IM = 0,80493, P = 0,0016; A-OXLDL vs USBL = 0,71930, P = 0,0084. Correlações do SLEDAI com as variáveis de risco foram altamente significativas somente nos subgrupos com níveis elevados de anticorpos (SLEDAI x A-OXLDL = 0,70366, P = 0,0107). CONCLUSÃO: A-LPL inicia o desenvolvimento de mutações de LDL, seguido pela produção de anticorpos, formação da placa e do risco coronariano em alguns pacientes com lúpus erimatoso sistêmico (LES).
INTRODUCTION: Premature development of atherosclerosis in systemic lupus erythematosus has been widely reported. Anti-lipoprotein lipase antibody may be one cause contributing to this disorder. OBJECTIVE: To assess the extent of coronary risk due to autoimmune antibodies in terms of carotid plaque in lupus patients. PATIENTS AND METHODS: We compared 114 documented lupus patients with 111 normal controls matched for sex and age. Anti-lipoprotein lipase (A-LPL), anti-oxidized low density lipoprotein (A-OXLDL), and anti-low density lipoprotein (A-LDL) were measured by enzme-linked immunoabsorbent assay. Low density lipoprotein-triglyceride (LDL-Trig) and high density lipoprotein-triglyceride (HDL-Trig) were also measured. Plaque was measured by bilateral carotid ultrasound. RESULTS: 45.6 percent of patients tested positive for A-LPL, and 34.4 percent for A-OXLDL. 44 percent of normal controls tested positive for A-LPL, and 20 percent for A-OXLDL. Risk increased sharply in subgroups with increased antibody levels. Patients with A-LPL and A-OXLDL > 0.40 (n = 12) showed coronary risk correlations of: A-LPL x LDL-Trig = 0.7008, P = 0.0111; bilateral ultrasound vs total cholesterol = 0.62205, P = 0.0308; LDL-Trig vs myocardial infarction (MI) = 0.76562, P = 0.0037; total triglycerides vs MI = 0.78191, P = 0.0027); LDL-Trig/LDL-cholesterol vs MI = 0.80493, P = 0.0016; A-OXLDL vs USBL = 0.71930, P = 0.0084. Correlations of SLEDAI with risk variables were highly significant only in subgroups of elevated antibody levels (SLEDAI x A-OXLDL = 0.70366, P = 0.0107). CONCLUSION: A-LPL initiates the development of LDL mutations, followed by antibody production, plaque formation and coronary risk in some SLE patients.
Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Aterosclerosis/inmunología , Autoanticuerpos/inmunología , Metabolismo de los Lípidos/inmunología , Lipoproteína Lipasa/inmunología , Lipoproteínas LDL/inmunología , Lupus Eritematoso Sistémico/inmunología , Aterosclerosis/etiología , Lupus Eritematoso Sistémico/complicacionesRESUMEN
Lipoprotein lipase (LPL) is a member of the lipase family, and LPL is known to hydrolyze triglyceride molecules found in lipoprotein particles. Understanding the pathogenesis of atherosclerosis in autoimmune diseases, particularly systemic lupus erythematosus (SLE), is vital to reduce morbidity and mortality of this disease. It is now recognized that SLE has a particular pattern of dyslipoproteinemia characterized by low HDL levels and increased triglycerides, which is aggravated by flare. Antilipoprotein lipase (anti-LPL) antibodies have been recently described in rheumatic diseases, mainly in SLE and systemic sclerosis (SSc). Several studies have reported a close link between antibodies, inflammation and lipoprotein levels and an increased risk of cardiovascular damage in this particular group of patients. These studies have emphasized the importance of rigorous clinical control of disease activity and prevention of cardiovascular risk factors. This review summarized the studies that have discussed the presence of anti-LPL in rheumatic diseases and other conditions and analyzed the importance of this antibody in the complex atherosclerotic process in autoimmune diseases.
Asunto(s)
Autoanticuerpos/fisiología , Lipoproteína Lipasa/inmunología , Aterosclerosis/etiología , Aterosclerosis/inmunología , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/inmunología , Humanos , Enfermedades Reumáticas/etiología , Enfermedades Reumáticas/inmunologíaRESUMEN
PURPOSE: Type V hyperlipidemia (HTG V) characterized by accumulation of both chylomicrons and VLDL results from a complex combination of genetic and environmental factors. However, a large proportion of sporadic cases remains largely unexplained. In a few cases, in a context of autoimmunity, auto-antibodies inhibiting lipoprotein lipase (LPL) activity have been incriminated. To establish their contribution to common type V hyperlipidemia in subjects with no apparent evidence of autoimmune background, we systematically screened the presence of these antibodies and their inhibition properties. METHODS: Screening for circulating anti-human LPL immunoglobulin G (anti-hLPL IgG) was carried out by western blotting in 63 subjects with HTG V and 77 controls. Inhibition of lipolytic activity by plasma from these patients was measured ex vivo. RESULTS: Anti-hLPL IgG was detectable in plasma from both controls and subjects with HTG V. After establishment of a threshold value corresponding to the 95th percentile of the control population, 27% of subjects with HTG V were found to have abnormal antibody levels (P<0.001). Only plasma obtained from these hyperchylomicronemic subjects with a high level of anti-hLPL IgG inhibited triglyceride hydrolysis whereas plasma from controls or HTG subjects with normal anti-hLPL IgG levels had no inhibitory effect (-13.5+/-3.4% vs 1.6+/-3.4%; P=0.04). However, no correlation was observed between anti-hLPL IgG levels, inhibitory effect and plasma triglyceride concentration. CONCLUSION: High levels of anti-hLPL immunoreactivity could be detected in only one out of four adult patients with type V hyperchylomicronemia. Furthermore, only a minority of these subjects (less than 10%) displayed both high anti-hLPL IgG levels and substantial inhibition (>20%) of plasma lipolysis. These auto-antibodies, in this setting only, might contribute to the occurrence of a minority of sporadic type V dyslipidemia cases.
Asunto(s)
Autoanticuerpos/química , Quilomicrones/química , Hiperlipidemias/sangre , Hiperlipidemias/inmunología , Lipoproteína Lipasa/sangre , Lipoproteína Lipasa/inmunología , Autoinmunidad , Western Blotting , Humanos , Hidrólisis , Hiperlipidemias/epidemiología , Inmunoglobulina G/química , Ligandos , Lipoproteína Lipasa/antagonistas & inhibidores , Modelos Biológicos , Triglicéridos/químicaRESUMEN
Lipopolysaccharide (LPS) administration down-regulates lipoprotein lipase (LPL) activity at the posttranscriptional level. Hypertriglyceridemia is the main metabolic consequence of this fall in LPL activity and is presumably involved in the innate immune response to infection. Nitric oxide (NO) has been implicated in LPS-induced down-regulation of LPL activity, but whether its effects are direct or indirect remains unclear. Here we examined the potential nitration of LPL in vivo in response to LPS challenge in rats. We found hypertriglyceridemia, iNOS expression, NO overproduction, and a generalized decrease in LPL activity in tissues 6 h after LPS administration. LPL sensitivity to nitration was first explored by in vitro exposure of bovine LPL to peroxynitrite, a reactive nitrogen species (RNS). Nitration was confirmed by anti-nitrotyrosine Western blot and subsequent identification of specific nitrotyrosine-containing LPL sequences by tandem mass spectrometry. Further analysis by targeted mass spectrometry revealed three in vivo-nitrated tyrosine residues in heart LPL from LPS-challenged rats. This is the first study to identify nitrated tyrosine residues in LPL, both in vitro and in vivo, and it demonstrates that LPL is a target for RNS in endotoxemia. These results indicate that LPL nitration may be a new mechanism of LPL activity regulation in vivo.
Asunto(s)
Endotoxemia/enzimología , Lipopolisacáridos/metabolismo , Lipoproteína Lipasa/metabolismo , Miocardio/enzimología , Óxido Nítrico/metabolismo , Animales , Bovinos , Endotoxemia/inducido químicamente , Endotoxemia/inmunología , Hipertrigliceridemia/etiología , Hipertrigliceridemia/metabolismo , Lipopolisacáridos/administración & dosificación , Lipoproteína Lipasa/química , Lipoproteína Lipasa/inmunología , Masculino , Miocardio/inmunología , Óxido Nítrico/química , Óxido Nítrico Sintasa de Tipo II/biosíntesis , Óxido Nítrico Sintasa de Tipo II/genética , Estrés Oxidativo , Ácido Peroxinitroso/química , Ácido Peroxinitroso/metabolismo , Ratas , Ratas Wistar , Espectrometría de Masas en Tándem , Tirosina/análogos & derivados , Tirosina/química , Tirosina/metabolismoRESUMEN
BACKGROUND: Antilipoprotein lipase (anti-LPL) antibodies were described in rheumatic diseases. In systemic lupus erythematosus they were highly associated with inflammatory markers and dyslipidemia, and may ultimately contribute to vascular damage. The relevance of this association in Takayasu's arteritis, which is characterized by major inflammatory process affecting vessels, has not been determined. OBJECTIVES: To analyze the presence of anti-LPL antibodies in patients with Takayasu's arteritis and its association with inflammatory markers and lipoprotein risk levels. Methods. Thirty sera from patients with Takayasu's arteritis, according to ACR criteria, were consecutively included. IgG anti-LPL was detected by a standard ELISA. Lipoprotein risk levels were evaluated according to NCEP/ATPIII. Inflammatory markers included ESR and CRP values. RESULTS: Takayasu's arteritis patients had a mean age of 34 years old and all were females. Half of the patients presented high ESR and 60% elevated CRP. Lipoprotein NCEP risk levels were observed in approximately half of the patients: 53% for total cholesterol, 43% for triglycerides, 16% for HDL-c and 47% for LDL-c. In spite of the high frequency of dyslipidemia and inflammatory markers in these patients no anti-LPL were detected. CONCLUSIONS: The lack of anti-LPL antibodies in Takayasu's disease implies distinct mechanisms underlying dyslipidemia compared to systemic lupus erythematosus.